PDCD1 and neoplasm: The inhibition of PD-L1 (programmed cell death ligand 1 (or CD274)/PD-1 (programmed cell death 1) (or CD279) signaling has demonstrated potential in the therapeutic approach to ES-SCLC by augmenting tumor-specific T-cell immunity [10,11,12,13].